Nabumetone and 6-mna pharmacokinetics, assessment of intrasubject variability and gender effect
American Journal of Therapeutics, ISSN: 1536-3686, Vol: 23, Issue: 6, Page: e1498-e1503
2016
- 2Citations
- 4Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Article Description
In this open-label, laboratory-blinded, 2-way single dose study in 24 volunteers of both sexes we found that (1) nabumetone reaches mean Cmax 6 SD of 0.56 6 0.20 mgL21 at mean tmax of 8.63 6 7.05 hours, and mean area under the curve (AUC)last of 18.07 6 7.19 hmgL21; (2) there are no statistically significant differences between both sexes in pharmacokinetics of nabumetone; (3) 6-methoxy-2-naphthylacetic acid (6-MNA) reaches higher AUClast in men compared with women (mean 6 SD, 721.23 6 185.53 hmgL21 and 545.27 6 97.69 hmgL21, respectively; P 5 0.013); (4) there is lower 6-MNA clearance in men (0.65 6 0.22 Lh21) in comparison with women (0.88 6 0.18 Lh21, P 5 0.019), (5) intersubject variability of nabumetone and 6-MNA is between 35%-45% and 10%-30% for all assessed pharmacokinetics parameters (AUClast, Cmax, partial AUC values); (6) intrasubject variability (ISCV) for AUClast is low, 15.59% and 6.40% for nabumetone and 6-MNA, respectively, (7) ISCV for Cmax is 13.66% and 5.42% for nabumetone and 6-MNA, respectively. Nabumetone thus belongs to compounds with low to moderate ISCV and therefore this product is expected to produce consistent effects in clinical practice.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84912019918&origin=inward; http://dx.doi.org/10.1097/mjt.0000000000000158; http://www.ncbi.nlm.nih.gov/pubmed/25393072; http://Insights.ovid.com/crossref?an=00045391-201611000-00032; https://journals.lww.com/00045391-201611000-00032; https://dx.doi.org/10.1097/mjt.0000000000000158; https://journals.lww.com/americantherapeutics/Abstract/2016/11000/Nabumetone_and_6_MNA_Pharmacokinetics,_Assessment.32.aspx
Ovid Technologies (Wolters Kluwer Health)
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know